Accéder au contenu
Merck

Interaction of epoxyeicosatrienoic acids and adipocyte fatty acid-binding protein in the modulation of cardiomyocyte contractility.

International journal of obesity (2005) (2014-11-06)
V Lamounier-Zepter, C Look, W-H Schunck, I Schlottmann, C Woischwill, S R Bornstein, A Xu, I Morano
RÉSUMÉ

Adipocyte fatty acid-binding protein (FABP4) is a member of a highly conserved family of cytosolic proteins that bind with high affinity to hydrophobic ligands, such as saturated and unsaturated long-chain fatty acids and eicosanoids. Recent evidence has supported a novel role for FABP4 in linking obesity with metabolic and cardiovascular disorders. In this context, we identified FABP4 as a main bioactive factor released from human adipose tissue that directly suppresses heart contraction in vitro. As FABP4 is known to be a transport protein, it cannot be excluded that lipid ligands are involved in the cardiodepressant effect as well, acting in an additional and/or synergistic way. We investigated a possible involvement of lipid ligands in the negative inotropic effect of adipocyte factors in vitro. We verified that blocking the CYP epoxygenase pathway in adipocytes attenuates the inhibitory effect of adipocyte-conditioned medium (AM) on isolated adult rat cardiomyocytes, thus suggesting the participation of epoxyeicosatrienoic acids (EETs) in the cardiodepressant activity. Analysis of AM for EETs revealed the presence of 5,6-, 8,9-, 11,12- and 14,15-EET, whereas 5,6-EET represented about 45% of the total EET concentration in AM. Incubation of isolated cardiomyocytes with EETs in similar concentrations as found in AM showed that 5,6-EET directly suppresses cardiomyocyte contractility. Furthermore, after addition of 5,6-EET to FABP4, the negative inotropic effect of FABP4 was strongly potentiated in a concentration-dependent manner. These data suggest that adipocytes release 5,6-EET and FABP4 into the extracellular medium and that the interaction of these factors modulates cardiac function. Therefore elevated levels of FABP4 and 5,6-EET in obese patients may contribute to the development of heart dysfunction in these subjects.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Diméthylsulfoxyde, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
Diméthylsulfoxyde, for molecular biology
Sigma-Aldrich
Diméthylsulfoxyde, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
Diméthylsulfoxyde, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
Acétonitrile, anhydrous, 99.8%
Sigma-Aldrich
Diméthylsulfoxyde, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
Indomethacin, 98.5-100.5% (in accordance with EP)
Sigma-Aldrich
Diméthylsulfoxyde, anhydrous, ≥99.9%
Sigma-Aldrich
Diméthylsulfoxyde, PCR Reagent
Sigma-Aldrich
Ethyl alcohol, Pure, 190 proof, ACS spectrophotometric grade, 95.0%
Sigma-Aldrich
Acétonitrile, electronic grade, 99.999% trace metals basis
Sigma-Aldrich
Indomethacin, meets USP testing specifications
Sigma-Aldrich
Nordihydroguaiaretic acid, ≥97.0% (HPLC)
Sigma-Aldrich
Diméthylsulfoxyde, meets EP testing specifications, meets USP testing specifications
Sigma-Aldrich
17-Octadecynoic acid, ≥95% (GC)
Sigma-Aldrich
8-Octanoyloxypyrene-1,3,6-trisulfonic acid trisodium salt, suitable for fluorescence, ≥90% (HPCE)
Sigma-Aldrich
Acétonitrile
Sigma-Aldrich
6-(2-Propargyloxyphenyl)hexanoic acid, ≥98%, solid